Domain Therapeutics

Pharmaceutical ManufacturingGrand Est, France11-50 Employees

Domain Therapeutics is a clinical-stage biopharmaceutical company focused on developing immunotherapies that target G protein-coupled receptors to address cancer. It emphasizes a biomarker-driven approach, aiming to tailor therapies to the unique signatures of individual tumors. With around twenty years of GPCR drug-discovery experience, the company has cultivated collaborations with major pharmaceutical partners to advance its programs. The company is based in Illkirch-Graffenstaden, in the Grand Est region of France, near Strasbourg.

Domain's pipeline centers on GPCR targets with a focus on immuno-oncology, including antibody and receptor-modulator programs designed to modulate the tumor microenvironment and signaling pathways. The organization operates globally and anchors its discovery and development on a proprietary cross-validation platform to prioritize candidate therapies with strong translational potential. In late 2025, the company announced the appointment of Jean-Marie Cuillerot as Chief Medical Officer, marking a leadership update. The business maintains a relatively small but international footprint, reflecting its clinical-stage status and ongoing partnerships.

Sign up for free to view info

Email Format Employee directory